Drug Profile
Hepatitis A vaccine inactivated - KM Biologics/Fujisawa
Alternative Names: Aimmugen; Chiba; SEIKENLatest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator National Institute of Health and Nutrition
- Developer Astellas Pharma; Daiichi Sankyo Company; KM Biologics; Mitsubishi Tanabe Pharma Corporation; National Institute of Health and Nutrition
- Class Hepatitis A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis A
Most Recent Events
- 01 Aug 2019 KM Biologics enters into a distribution agreement with Meiji Seika Pharma for its human vaccines portfolio (9307110; 9258921)
- 31 Jul 2019 Astellas Pharma and KM Biologics agreement for human vaccines expires (9307110; 9258921)
- 31 Mar 2018 Daiichi Sankyo and Kaketsuken terminates an cooperative sales agreement for Influenza HA Vaccine